OncoCyte's (OCX) Equal Weight Rating Reiterated at Stephens

Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […]

Related Keywords

United States ,Andrew Arno ,Goldman Sachs Group Inc ,Oncocyte Corporation ,Cubist Systematic Strategies ,Oncocyte Company Profile ,Vanguard Group Inc ,Securities Exchange Commission ,Raymond James Financial Services Advisors Inc ,Free Report ,Cyte Stock Down ,Director Andrew Arno ,Exchange Commission ,Broadwood Partners ,James Financial Services Advisors ,Sachs Group ,Get Free Report ,Cyte Corporation ,Oncocyte Daily ,Oncocyte ,Nasdaq Ocx ,Socx ,Medical ,Reiterated Rating ,Stephens ,